<DOC>
	<DOCNO>NCT00521261</DOCNO>
	<brief_summary>RATIONALE : Giving high dos chemotherapy donor stem cell transplant help stop growth cancer cell . It also stop patient 's immune system reject donor 's stem cell . Colony stimulate factor , aldesleukin GM-CSF , may increase number immune cell find bone marrow peripheral blood may help immune system recover side effect chemotherapy . The donated stem cell may replace patient 's immune cell help destroy remain cancer cell ( graft-versus-tumor effect ) . Giving infusion donor 's T cell treat antibody transplant may help increase effect . Sometimes transplanted cell donor also make immune response body 's normal cell . Giving tacrolimus mycophenolate mofetil transplant may stop happen . PURPOSE : This phase I trial study side effect best dose donor T cell give together low-dose aldesleukin low-dose GM-CSF donor stem cell transplant treat patient relapsed refractory non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Donor T Cells , Low-Dose Aldesleukin , Low-Dose GM-CSF After Donor Stem Cell Transplant Treating Patients With Relapsed Refractory Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose donor-derived allogeneic anti-CD3 X anti-CD20 bispecific antibody ( CD20Bi ) -armed activated T cell ( ATC ) give low-dose aldesleukin low-dose sargramostim ( GM-CSF ) allogeneic stem cell transplantation patient relapse refractory CD20-positive non-Hodgkin lymphoma . - Perform trafficking study use indium I 111-labeled unarmed ATC ATC arm CD20Bi patient evaluable lymphoma site determine whether arm ATC specifically traffic tumor sit correlate data CT PET scan . - Evaluate immune response immune reconstitution T B cell . OUTLINE : All patient receive high-dose chemotherapy standard care disease . Peripheral blood lymphocyte obtain HLA-identical sibling donor culture obtain activated T cell ( ATC ) , subsequently arm CD20 bispecific antibody ( CD20Bi ) cryopreserved later use . Patients undergo allogeneic hematopoietic stem cell transplantation ( SCT ) . Patients receive ATC-CD20Bi IV day 40 , 70 , 100 , 130 , 160 SCT . Patients receive low-dose aldesleukin subcutaneously ( SC ) daily 7 day begin within 24 hour ATC-CD20Bi infusion low-dose sargramostim ( GM-CSF ) SC every day 3 dos begin within 24 hour infusion ATC-CD20Bi . Patients also receive tacrolimus mycophenolate mofetil standard graft-vs-host disease prophylaxis . Treatment continue absence unacceptable toxicity . Some patient well-defined evaluable mass receive indium I 111 ( ^111I ) -labeled ATC-CD20Bi IV ^111I-labeled unarmed ATC undergo whole-body image traffic study . After completion study treatment , patient follow 6 month , 12 month , annually thereafter .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Bispecific</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm CD20positive nonHodgkin lymphoma Relapsed , resistant , chemorefractory disease Must available HLAidentical sibling donor No significant skin breakdown tumor disease PATIENT CHARACTERISTICS : ECOG performance status 02 DLCO ≥ 50 % normal No symptomatic obstructive restrictive pulmonary disease Creatinine ≤ 2.0 mg/dL OR creatinine clearance ≥ 60 mL/min Direct bilirubin ≤ 2.0 mg/dL ( even attributable disease ) SGOT SGPT ≤ 2.5 time normal ( even attributable disease ) No history severe hepatic dysfunction No severe cardiac dysfunction LVEF ≥ 50 % gate blood pool scan No major heart disease Patients congenital acquire heart disease cardiac arrhythmia must undergo cardiology consultation evaluation No active infection Patients see evaluated dentist teeth clean examination potential source infection ineligible HIV antibody negative No uncompensated major thyroid adrenal dysfunction Not pregnant nursing Persistently elevate systolic blood pressure ( BP ) ≥ 130 mm Hg diastolic BP ≥ 80 mm Hg must control antihypertensive agent least 7 day prior initiation cell therapy Patients essential hypertension control medication eligible PRIOR CONCURRENT THERAPY : Prior total dose doxorubicin daunorubicin must less 450 mg/m^2 unless endomyocardial biopsy show less grade 2 drug effect No concurrent nitroglycerin preparation angina pectoris No antiarrhythmic drug major ventricular dysrhythmias</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>Waldenstrom macroglobulinemia</keyword>
	<keyword>adult nasal type extranodal NK/T-cell lymphoma</keyword>
	<keyword>recurrent adult grade III lymphomatoid granulomatosis</keyword>
	<keyword>cutaneous B-cell non-Hodgkin lymphoma</keyword>
</DOC>